surmount-1 tirzepatide non-diabetic obesity weight loss In the trial (published in NEJM in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor surmount-1 Gastrointestinal tolerability and weight reduction

Nausea typically emerges within the first two weeks of starting treatment or after a dose increase

Thats major for longevity because cutting back on alcohol and other substances is associated with lower risks of chronic diseaseand in turn a longer, healthier life

However, it also acts as a weight loss drug, aiding significant weight loss by slowing digestion and serving as a dual targeted treatment with both glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist properties

They come as prefilled injection pens

10.1038/s41419-022-04764-2 133 TangD.ChenX.KangR.KroemerG

The FDA found that the shortage of tirzepatide (Mounjaro and Zepbound) ended in December